TY  - JOUR 
AU  - Jimeno Ruiz, Sara
AU  - Peláez Laderas, Adrián
AU  - Labourt, Agustín
AU  - Acuña, Florencia Mercedes
AU  - Linares, Lucía
AU  - Llana Martín, Isabel
AU  - Calle Gómez, Ángeles
AU  - Natalini Martínez, Silvina
PY  - 2024
SN  - 076-393X
UR  - http://hdl.handle.net/20.500.12020/1394
AB  - Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease. Although clinical trials have demonstrated the efficacy of...
LA  - en
PB  - MDPI
TI  - Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain
DO  - https://doi.org/10.3390/vaccines12101160
T2  - Vaccines
M2  - 1160
KW  - Respiratory Syncytial Virus (RSV)
KW  - Nirsevimab
KW  - Pediatric Respiratory Care
KW  - RSV-related Lower Respiratory Tract Infection
KW  - Healthcare Burden Reduction
VL  - 12
ER  -